Home/Plus Therapeutics/Toral Patel, M.D.

TP

Toral Patel, M.D.

Key Opinion Leader

Plus Therapeutics

Therapeutic Areas

Oncology Central Nervous System Cancers Liver Cancers

Plus Therapeutics Pipeline

Drug	Indication	Phase
REYOBIQ™ (rhenium Re186 obisbemeda)	Recurrent Glioblastoma	Phase 2
188RNL-BAM	Hepatocellular Carcinoma	Preclinical

Leadership Team at Plus Therapeutics

Marc H. Hedrick, M.D.

President & Chief Executive Officer

Andrew Brenner, M.D., Ph.D.

Principal Investigator / Key Opinion Leader

View full Plus Therapeutics profile